Novo Nordisk A/S (NYSE:NVO) Coverage Initiated at Wolfe Research

Analysts at Wolfe Research started coverage on shares of Novo Nordisk A/S (NYSE:NVO) in a research report issued to clients and investors on Thursday, Marketbeat reports. The brokerage set a “peer perform” rating on the stock.

Several other brokerages have also weighed in on NVO. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Citigroup initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. Finally, Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Stock Down 1.1%

Shares of NVO stock opened at $36.01 on Thursday. Novo Nordisk A/S has a one year low of $35.85 and a one year high of $81.44. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The stock has a fifty day moving average price of $45.92 and a 200 day moving average price of $50.48. The stock has a market cap of $160.78 billion, a P/E ratio of 10.38 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors have recently added to or reduced their stakes in the company. Capital International Investors increased its holdings in shares of Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after buying an additional 6,092,192 shares in the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Novo Nordisk A/S by 6.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after acquiring an additional 969,916 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Novo Nordisk A/S by 5.1% in the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after acquiring an additional 717,719 shares in the last quarter. Morgan Stanley grew its position in Novo Nordisk A/S by 3.5% during the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after acquiring an additional 428,660 shares during the last quarter. Finally, Folketrygdfondet grew its position in Novo Nordisk A/S by 1.2% during the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after acquiring an additional 117,370 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves Awiqli (insulin icodec‑abae), the first once‑weekly basal insulin for adults with type 2 diabetes — expands treatment choices, may improve adherence vs daily basal insulin and supports a U.S. launch in the second half of 2026. US FDA approves Novo’s insulin injection for type 2 diabetes
• Positive Sentiment: Corporate governance/market strategy bolstered by appointment of Mars CEO Poul Weihrauch as a board observer — intended to strengthen Novo’s positioning and commercial insights in the competitive U.S. obesity market. Novo Nordisk appoints Mars CEO as board observer
• Neutral Sentiment: Filed updated Articles of Association and capital‑increase mandate — routine corporate housekeeping that can enable share issuance or compensation plans but has no immediate earnings impact. Articles of Association for Novo Nordisk A/S 2026
• Neutral Sentiment: Mixed analyst coverage: Wolfe Research started coverage with a “peer perform” rating and some brokers give neutral takes on the pipeline — underscores divergent views on growth sustainability vs valuation.
• Neutral Sentiment: Pipeline commentary: promising signals for next‑generation candidates (e.g., UBT251 triple‑agonist) but analysts flag that new oral drug trends and incremental data so far are not yet transformative. GLP‑1 pipeline shows promise but oral drug trends give analysts pause
• Negative Sentiment: Bernstein initiated coverage with an Underperform rating and a low price target, warning the company’s earnings downgrade cycle may not be over — a clear near‑term headwind for sentiment and the stock. Bernstein initiates coverage with Underperform
• Negative Sentiment: Recent headlines and analyst notes have coincided with share weakness and short‑term selling — valuation concerns (forward P/E in the low double digits vs peers) and profit‑taking after prior rallies are weighting the stock. Stock slides as market rises

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.